Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 8/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.37 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25427665 | 0.86 | S1PR1 (0.48) | GRM2S1PR1SGPL1S1PR3 | |
| SCHEMBL5536727 | 0.82 | GRM2 (0.44) | GRM2SIRT2HRH4HRH3 | |
| SCHEMBL5536723 | 0.82 | SIRT2 (0.45) | GRM2SIRT2HRH4HRH3S1PR1 | |
| SCHEMBL8026316 | 0.81 | HRH3 (0.38) | HRH4HRH3 | |
| SCHEMBL8690822 | 0.81 | SIRT2 (0.46) | GRM2SIRT2S1PR1SGPL1S1PR3 | |
| SCHEMBL5537744 | 0.81 | SIRT2 (0.44) | GRM2SIRT2S1PR1SGPL1S1PR3 | |
| SCHEMBL5537748 | 0.81 | GRM2 (0.46) | GRM2SIRT2HRH4HRH3 | |
| SCHEMBL2059453 | 0.78 | GRM2 (0.44) | GRM2SIRT2HRH3 | |
| SCHEMBL8688839 | 0.78 | LPL (0.40) | GRM2SIRT2S1PR1SGPL1S1PR3 | |
| SCHEMBL20958651 | 0.78 | AKR1B1 (0.41) | GRM2SIRT2HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
| US-6159964-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0895475-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0869787-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0895475-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-10 | — | — | EP | disclosed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | GRM2 913/4885SIRT2 2524/4885HRH4 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.